sharon sanders
Editor-in-Chief & President
Serologic testing of U.S. blood donations to identify SARS-CoV-2-reactive antibodies: December 2019-January 2020
Sridhar V Basavaraju, MD, Monica E Patton, MD, Kacie Grimm, Mohammed Ata Ur Rasheed, PhD, Sandra Lester, PhD, Lisa Mills, PhD, Megan Stumpf, Brandi Freeman, PhD, Azaibi Tamin, PhD, Jennifer Harcourt, PhD ... Show more
Clinical Infectious Diseases, ciaa1785, https://doi.org/10.1093/cid/ciaa1785
Published:
30 November 2020
Abstract
Background
SARS-CoV-2, the virus that causes COVID-19 disease, was first identified in Wuhan, China in December 2019, with subsequent worldwide spread. The first U.S. cases were identified in January 2020.
Methods
To determine if SARS-CoV-2 reactive antibodies were present in sera prior to the first identified case in the U.S. on January 19, 2020, residual archived samples from 7,389 routine blood donations collected by the American Red Cross from December 13, 2019 to January 17, 2020, from donors resident in nine states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington, and Wisconsin) were tested at CDC for anti-SARS-CoV-2 antibodies. Specimens reactive by pan-immunoglobulin (pan Ig) enzyme linked immunosorbent assay (ELISA) against the full spike protein were tested by IgG and IgM ELISAs, microneutralization test, Ortho total Ig S1 ELISA, and receptor binding domain / Ace2 blocking activity assay.
Results
Of the 7,389 samples, 106 were reactive by pan Ig. Of these 106 specimens, 90 were available for further testing. Eighty four of 90 had neutralizing activity, 1 had S1 binding activity, and 1 had receptor binding domain / Ace2 blocking activity >50%, suggesting the presence of anti-SARS-CoV-2-reactive antibodies. Donations with reactivity occurred in all nine states.
Conclusions
These findings suggest that SARS-CoV-2 may have been introduced into the United States prior to January 19, 2020.
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1785/6012472
Sridhar V Basavaraju, MD, Monica E Patton, MD, Kacie Grimm, Mohammed Ata Ur Rasheed, PhD, Sandra Lester, PhD, Lisa Mills, PhD, Megan Stumpf, Brandi Freeman, PhD, Azaibi Tamin, PhD, Jennifer Harcourt, PhD ... Show more
Clinical Infectious Diseases, ciaa1785, https://doi.org/10.1093/cid/ciaa1785
Published:
30 November 2020
Abstract
Background
SARS-CoV-2, the virus that causes COVID-19 disease, was first identified in Wuhan, China in December 2019, with subsequent worldwide spread. The first U.S. cases were identified in January 2020.
Methods
To determine if SARS-CoV-2 reactive antibodies were present in sera prior to the first identified case in the U.S. on January 19, 2020, residual archived samples from 7,389 routine blood donations collected by the American Red Cross from December 13, 2019 to January 17, 2020, from donors resident in nine states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington, and Wisconsin) were tested at CDC for anti-SARS-CoV-2 antibodies. Specimens reactive by pan-immunoglobulin (pan Ig) enzyme linked immunosorbent assay (ELISA) against the full spike protein were tested by IgG and IgM ELISAs, microneutralization test, Ortho total Ig S1 ELISA, and receptor binding domain / Ace2 blocking activity assay.
Results
Of the 7,389 samples, 106 were reactive by pan Ig. Of these 106 specimens, 90 were available for further testing. Eighty four of 90 had neutralizing activity, 1 had S1 binding activity, and 1 had receptor binding domain / Ace2 blocking activity >50%, suggesting the presence of anti-SARS-CoV-2-reactive antibodies. Donations with reactivity occurred in all nine states.
Conclusions
These findings suggest that SARS-CoV-2 may have been introduced into the United States prior to January 19, 2020.
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1785/6012472